ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data
New benchmark confirms LENS ai 's ability to accurately predict binding on 17 previously unseen antibody-antigen complexes, achieving near-crystallography precision without prior training data.
Article content
AUSTIN, Texas — ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ('IPA' or the 'Company'), an AI-powered biotherapeutics company, today announced a new validation study supporting the generalizability of its proprietary epitope mapping platform, LENS ai, powered by IPA's patented HYFT® technology. The newly released benchmark shows that the platform consistently delivers high predictive performance, even on complexes not used during training.
Article content
'It's generally assumed that AI can only make accurate predictions if it has seen similar data before,' said Dr. Jennifer Bath, CEO of ImmunoPrecise. 'But this benchmark proves otherwise: LENS ai accurately mapped antibody binding sites on entirely new antibody – protein complexes-none of which were used in training. Not the antibodies. Not the targets. Not the complexes. And the predictions aligned with wet-lab results. This is a major breakthrough in generalizing AI for therapeutic discovery, made possible by our proprietary technology, which captures functional meaning instead of memorizing shapes. It shows that AI doesn't always need massive data to be powerful and accurate – it just needs the right kind.'
Article content
LENS ai Epitope Mapping uses artificial intelligence to pinpoint where antibodies are most likely to attach to disease-related proteins – helping scientists design better treatments faster. Unlike traditional methods that take months and require lab work, LENS ai delivers results in hours – using just the digital sequences – cutting timelines, eliminating the need to produce expensive materials, reducing guesswork, and unlocking faster paths to new treatments.
Article content
In a new benchmark study, LENS ai was tested on 30 antibody-protein pairs, 17 of which the platform had never seen before. Despite having no prior exposure to these molecules, LENS ai achieved prediction scores nearly identical to those from its original training data. This score, known as AUC (Area Under the Curve), is a widely accepted measure of accuracy in computational biology.
Article content
The consistent performance on entirely new, unseen complexes confirms that LENS ai 's artificial intelligence can reliably analyze and predict antibody binding – even for molecules outside its training set. This breakthrough demonstrates LENS ai 's power to generalize across diverse biological structures, making it a valuable tool for accelerating real-world drug discovery.
Article content
Why This Benchmark Matters
Article content
In the new study, LENS ai delivered high accuracy results on 17 antibody-protein complexes the platform had never seen before as it did on familiar training examples – proving true generalization, not memorization. Because no new wet-lab work or x-ray structures were required, researchers gain speed, reproducibility, and major cost savings, while freeing scarce lab resources for confirmatory or downstream assays.
Article content
What It Means for Partners and Investors
Article content
With LENS ai already embedded in collaborations across big pharma and biotech, ImmunoPrecise is scaling access through secure APIs and custom partnerships. The platform helps researchers compress discovery timelines, reduce risk, and unlock previously unreachable targets – positioning the company and its investors at the forefront of AI-driven antibody therapeutics.
Article content
For more technical detail and full benchmark results, explore two complementary case studies that illustrate the power and flexibility of LENS ai Epitope Mapping.
Article content
ai
Article content
's breakthrough ability to accurately map binding sites on a completely
Article content
'unseen' target
Article content
, with no prior exposure to the antibody, the antigen, or their structure.
Article content
These examples underscore how LENS ai performs both in well-characterized systems and in novel, previously untrained scenarios—validating its generalizability and real-world readiness.
Article content
About ImmunoPrecise Antibodies Ltd.
Article content
ImmunoPrecise (NASDAQ: IPA) is a global leader in AI-powered biotherapeutic discovery and development. Its proprietary HYFT technology and LENSai™ platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. IPA partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models.
Article content
Forward-Looking Statements
Article content
This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as 'expects,' 'intends,' 'plans,' 'anticipates,' 'believes,' or similar expressions, or by statements that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur or be achieved. These statements include, but are not limited to, statements regarding the performance, scalability, and broader application of the LENSai™ and HYFT® platforms; the generalizability of the Company's AI models to novel therapeutic targets; the role of AI in accelerating antibody discovery; and the Company's future scientific, commercial, and strategic developments.
Article content
Forward-looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company's control. These factors include, but are not limited to, the pace of scientific and technological innovation, risks related to model validation and generalizability in real-world settings, intellectual property protection, strategic partner adoption, regulatory pathways, and market demand for AI-driven therapeutic platforms.
Article content
Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information regarding risks and uncertainties is included in the Company's Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Company's SEDAR+ profile at
Article content
www.sedarplus.ca
Article content
and EDGAR profile at
Article content
www.sec.gov/edgar
Article content
). Should any of these risks materialize, actual results could vary significantly from those currently anticipated.
Article content
Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances.
Article content
Article content
Article content
Article content
Contacts
Article content
Investor Relations Contact
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
19 minutes ago
- Globe and Mail
The Buzbee Law Firm Urges National Push for Corporate Accountability
Texas firm behind $640M verdict says real change starts with citizen action and jury service The Buzbee Law Firm, a nationally recognized litigation firm based in Texas, is calling on citizens, business leaders, and jurors to take a more active role in holding corporations accountable for negligence and misconduct. In a newly featured article titled 'How Landmark Verdicts Like the $640M Loree Case Are Reshaping Corporate Accountability in America,' the firm reflects on the implications of the historic wrongful death verdict they secured earlier this year—and what it means for everyday people. 'When a jury delivers a $640 million verdict, it's not just about compensation—it's about consequences,' a firm representative said. 'It's about signaling that companies can't ignore safety without facing serious repercussions.' The firm's message is clear: meaningful accountability starts in communities—not just in courtrooms, but in workplaces, homes, and on juries. A Wake-Up Call for Corporate America The Loree v. TNT Crane & Rigging case captured national attention when a Houston jury awarded $640 million—including $480 million in punitive damages—after David Lester Loree II was killed during a crane operation. The defendant's initial settlement offer was just $6.9 million. The jury's decision sent a powerful message. 'The jury didn't just want to make the family whole,' The Buzbee Law Firm stated. 'They wanted to tell every company watching: if you cut corners and someone gets hurt, you will be held accountable.' According to the National Center for State Courts, civil juries now return verdicts in favor of plaintiffs nearly 60% of the time in workplace injury and wrongful death cases—up from 52% just a few years ago. Meanwhile, the average jury award in these cases has increased 40% since 2015. What You Can Do Right Now The Buzbee Law Firm isn't asking for donations or proposing legislation. Instead, they are encouraging everyday Americans to take five simple actions that can drive systemic change: Serve When Called: 'Jury duty isn't a burden—it's a responsibility. Jurors are the last line of defense when corporations fail the public.' Speak Up in the Workplace: Identify and report unsafe conditions. Encourage transparency and accountability at every level. Vote for Oversight: Elect officials who prioritize consumer safety and corporate regulation. Support Transparency: Elevate stories of corporate misconduct and legal reform. Awareness breeds action. Audit Internally: Business leaders should review safety protocols and training now—before a verdict forces their hand. 'You don't need to be in a courtroom to protect your community,' the firm noted. 'You just need to care enough to act—wherever you are.' Making Negligence Too Expensive to Ignore The firm believes large verdicts like the one in Loree are key to real change—not because they destroy companies, but because they force decision-makers to rethink how they measure risk. 'After a major verdict, we often see companies overhaul training programs, replace leadership, and install new safety systems,' The Buzbee Law Firm said. 'Not because they want to—but because they have to.' A Texas Case with National Consequences The Loree verdict is already influencing how corporations and attorneys approach risk management and trial strategy nationwide. But for The Buzbee Law Firm, the broader takeaway is about community power. 'This case wasn't just about Texas. It was about what happens when ordinary people—jurors, workers, voters—demand better. That's how real accountability begins.' To read more, visit the website here. About The Buzbee Law Firm The Buzbee Law Firm is a Houston-based trial firm with a national reputation for high-impact litigation. With billions recovered in verdicts and settlements, the firm handles cases involving catastrophic injury, commercial disputes, and corporate negligence. They are dedicated to protecting the public and holding powerful entities accountable. Contact: info@ Media Contact Company Name: The Buzbee Law Firm Contact Person: Tony Buzbee Email: Send Email Country: United States Website:
Globe and Mail
34 minutes ago
- Globe and Mail
IBM's Neudesic Boosts Cloud Security Capabilities: An Ace Up Sleeve?
Neudesic, a subsidiary of International Business Machines Corporation IBM, has renewed its Cloud Security Specialization with Microsoft Corporation MSFT to continue delivering enterprise-grade security solutions across hybrid and multi-cloud environments. The Microsoft certification validates Neudesic's ability to help clients protect critical infrastructure and data across Azure and on-premises systems by deploying Microsoft-native security capabilities. The renewal further underscores Neudesic's deep integration with the Microsoft ecosystem, leveraging the latter's Zero Trust model to offer customized solutions that meet the highest standards for performance, governance and compliance. IBM acquired Neudesic, a leading U.S. cloud services consultancy specializing primarily in the Microsoft Azure platform, in February 2022. The buyout significantly expanded IBM's portfolio of hybrid multi-cloud services, offering digital transformation services across advisory, application development, cloud migration, DevOps, integration, data engineering, data visualization and hyper-automation. It extended IBM Consulting's skills and certifications across the health and life sciences, financial services, energy and utilities, professional services and retail industries. Neudesic's Microsoft certification provides clients with the confidence of working with a trusted advisor who would help reduce risk, improve resiliency and implement scalable security strategies across Azure and hybrid environments. This, in turn, will enable Neudesic to strengthen its leadership position in cloud security, likely translating to incremental revenues for its parent firm, IBM. Other Tech Firms With Microsoft Cloud Security Specialization Rubrik, Inc. RBRK boasts the Microsoft Cloud Security Specialization, which validates its robust capabilities in securing complex Azure-based environments, particularly in backup, posture management, DLP, recovery planning and generative AI-powered incident response. It integrates Rubrik Security Cloud with Microsoft Sentinel and Azure OpenAI Service to boost cyber recovery capabilities via generative AI. Rubrik recently launched a cyber resilience solution for Azure Blob Storage, offering features like data classification, posture assessment, continuous monitoring, cost management and rapid cleanup and recovery. CDW Corporation CDW has achieved all Microsoft Advanced Security Specializations, including Cloud Security, demonstrating end-to-end Azure expertise. The specialization signals CDW's capability to implement multi-layered protection across hybrid environments using Defender XDR, Sentinel, Azure services and advanced managed security services. The Microsoft certification also validates CDW's expertise in deploying, managing and securing Azure cloud workloads for enterprise-scale clients while handling compliance and governance. IBM's Price Performance, Valuation and Estimates IBM has surged 65.9% over the past year, outperforming the industry 's growth of 8.9%. Image Source: Zacks Investment Research From a valuation standpoint, IBM trades at a forward price-to-sales ratio of 4, above the industry. The Zacks Consensus Estimate for IBM's earnings for 2025 has been on the rise over the past 60 days. IBM currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Microsoft Corporation (MSFT): Free Stock Analysis Report CDW Corporation (CDW): Free Stock Analysis Report Rubrik, Inc. (RBRK): Free Stock Analysis Report
Globe and Mail
an hour ago
- Globe and Mail
Boeing Stock Set for a Ride as NASA Progresses in Artemis II Program
NASA's Artemis II mission, the first crewed flight in its lunar return program, set to launch in April 2026, has reached critical milestones in recent months, reigniting investor interest in aerospace giant Boeing BA, a key contractor in the Space Launch System (SLS) program. On July 2, 2025, NASA announced on its Facebook page that the Program Specific Engineering Test for the Artemis II core stage had been completed. In early June, the Artemis II team conducted its first mission simulation to rehearse lunar science operations for the upcoming crewed mission. Earlier, in March, the integration of the Artemis II SLS core stage with its solid rocket boosters was successfully completed, which was another key milestone in preparing the rocket for launch. To this end, it is imperative to mention that the SLS rocket, designed to carry astronauts farther into space than ever before, is led by Boeing as the prime contractor for its core stage, upper stage, and avionics systems. The jet giant is currently building the core stages for all future Artemis missions. Thus, for Boeing, Artemis II represents more than just a technological triumph — it's a strategic revenue driver. With the company's Defense, Space & Security segment accounting for nearly 36% of total revenues in 2024, space programs like Artemis are key to Boeing's efforts to gain from a diversified portfolio beyond its struggling commercial aviation business and provide it with a significant financial cushion. With Artemis II on track, NASA's commitment to sustaining the Artemis program through Artemis III and beyond implies recurring revenue potential for Boeing over the long run, given its deep involvement in every SLS flight configuration. As investor interest in space stocks has been gaining increasing traction these days, the continued success of the Artemis mission should strengthen Boeing's positioning in the $500 billion global space economy and offer a promising growth vector for its shares. The potential upside reflected in BA's price target further supports this thesis. Based on short-term price targets provided by 22 analysts, the average Zacks price target for Boeing implies a 6.4% upside from its last closing price. Other Space Stocks Warrant a Look Other stocks, involved in the SLS program and Artemis missions, like Lockheed Martin LMT and L3Harris Technologies Inc. LHX, also stand to benefit from the steady progress of the Artemis II mission. Notably, Lockheed is the prime contractor involved in the construction of Orion, the spacecraft that will carry the crew of four astronauts in the Artemis II mission. In May 2025, LMT achieved a significant milestone in the development of NASA's Orion spacecraft by officially transferring it to NASA's Exploration Ground Systems team, following the completion of the spacecraft's assembly and testing. On the other hand, L3Harris is involved in the Artemis II mission through its Aerojet Rocketdyne business unit, which provides the RS-25 engines that power the SLS core stage. In May 2025, Aerojet Rocketdyne completed installation of all four RS-25 main engines on the core stage of NASA's second SLS exploration rocket, which will be used in the Artemis II mission. The Zacks Rundown for BA Shares of Boeing have risen 22% year to date compared with the industry 's growth of 22.2%. From a valuation standpoint, BA is currently trading at a forward 12-month sales multiple of 1.80X, a roughly 18.9% discount when stacked up with the industry average of 2.22X. The Zacks Consensus Estimate for BA's 2025 and 2026 sales implies a year-over-year uptick of 25.6% and 16.2%, respectively. The same for its earnings per share for 2025 has moved north over the past 60 days, while the same for 2026 has moved south. BA stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Boeing Company (BA): Free Stock Analysis Report Lockheed Martin Corporation (LMT): Free Stock Analysis Report L3Harris Technologies Inc (LHX): Free Stock Analysis Report This article originally published on Zacks Investment Research (
